VLDLR and inherited lipid metabolism disorder: Dyslipidaemia is a well-known dose-dependent adverse effect of mTOR inhibitors that is thought to occur through down-regulation of low-density lipoprotein receptors and inhibition of lipoprotein lipase activity [16].